Market Place
Sourcing Support
OSE Immunotherapeutics Presents Tedopi Phase 2 Results
23 Apr 2026 //
PHARMIWEB
OSE Immunotherapeutics Evolves Its Leadership Team
14 Apr 2026 //
GLOBENEWSWIRE
OSE Immunotherapeutics To Present At Investor Conferences
23 Mar 2026 //
GLOBENEWSWIRE
Boehringer Axes MASH Deal After OSE Asset Fails To Show Efficacy
02 Mar 2026 //
FIERCE BIOTECH
OSE Gets Second Positive IDMC Nod for Tedopi Ph 3 NSCLC Trial
26 Feb 2026 //
PHARMIWEB
OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan
09 Dec 2025 //
GLOBENEWSWIRE
OSE Immuno Announces Strategic Amendment to AbbVie
09 Dec 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Gets (IDMC) Nod To Proceed Tedopi Ph 3
17 Nov 2025 //
GLOBENEWSWIRE
OSE Shows Poster On OSE-Cytomask Cis-Demasking Cytokine Tech
07 Nov 2025 //
GLOBENEWSWIRE
General Meeting Update for September 30, 2025
12 Sep 2025 //
GLOBENEWSWIRE
OSE, FoRT Complete Enrollment of Ph 2 Tedopi+Nivolumab NSCLC
11 Sep 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Urges Support for Strategy and Governance
09 Sep 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reaffirms Strategic Priorities, Shares
29 Aug 2025 //
GLOBENEWSWIRE
Thomas Gidoin Named CFO at OSE Immunotherapeutics
20 Aug 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Launches Newsletter for Retail Investors
17 Jul 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics & Boehringer Ingelheim to Present Clinical
23 May 2025 //
GLOBENEWSWIRE
OSE to lead mRNA project with €1.3M from French government
21 May 2025 //
FIERCE BIOTECH
OSE Immuno: 90% Stay in Remission with Lusvertikimab Extension
05 May 2025 //
GLOBENEWSWIRE
Immuno-Oncology Results Presented at AACR Annual Meeting 2025
30 Apr 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports 2024 Financial Results
26 Mar 2025 //
GLOBENEWSWIRE
Ose Immune Report Positive Ph II TEDOPaM Trial In Pancreatic Cancer
11 Mar 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Hosts KOL Webinar on Lusvertikimab and IBD
06 Mar 2025 //
GLOBENEWSWIRE
OSE Immuno Reports Full Ph 2 Lusvertikimab Data In Ulcerative Colitis
24 Feb 2025 //
GLOBENEWSWIRE
OSE Immuno Presents Preclinical Lusvertikimab Data In Chronic Colitis
20 Feb 2025 //
GLOBENEWSWIRE
OSE Immuno, Scienta Lab Partner To Leverage AI In Immunotherapy
29 Jan 2025 //
GLOBENEWSWIRE
OSE Immuno Presents Anti-IL-7R Lusvertikimab In Ulcerative Colitis
28 Jan 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics to Present Lusvertikimab Ph 2 Result at ECCO
18 Dec 2024 //
GLOBENEWSWIRE
OSE Reports Positive Progress For Tedopi® Cancer Vaccine
11 Dec 2024 //
GLOBENEWSWIRE
OSE Immuno Announces Positive Lusvertikimab UC Phase 2 Data
04 Nov 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Presents New “Cis-Demasking” Technology
17 Oct 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Announces H1 2024 Results
26 Sep 2024 //
GLOBENEWSWIRE
OSE Immuno Launches Artemia Phase 3 Study for Cancer Vaccine
10 Sep 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Enters Agreement With MSK For CAR T-Cell Therapies
25 Jun 2024 //
PHARMABIZ
OSE Immunotherapeutics Presents MRNA Platform Data At FOCIS Annual Meeting
20 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Receives Public Funding for Tedopi® Trial
10 Apr 2024 //
GLOBENEWSWIRE
OSE Immuno Presents First Positive Clinical Results With its anti-PD1 OSE-279
16 Oct 2023 //
BUSINESSWIRE
OSE: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients
11 Sep 2023 //
BUSINESSWIRE
OSE Immuno Announces US Patent Granted for the Use of Tedopi in Cancer Patients
04 Jul 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Provides Regulatory Update on Tedopi
15 Feb 2023 //
BUSINESSWIRE
